Sobi strengthens inflammation franchise by acquiring global rights for emapalumab from Novimmune
Strategic partnership to develop and commercialise emapalumab, a highly attractive late stage orphan drug candidate that addresses a high unmet medical need in primary Haemophagocytic lymphohistiocytosis (HLH)